1 – 10 of 45
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
2024) In Leukemia and Lymphoma(
- Contribution to journal › Article
-
Mark
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients
(
- Contribution to journal › Article
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
(
- Contribution to journal › Article
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
- 2022
-
Mark
Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia
2022) In Leukemia(
- Contribution to journal › Letter
- 2021
-
Mark
Impact of treatment delay in acute myeloid leukemia revisited
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Parental origin of monosomy 7 in acute leukaemia
2021) In British Journal of Haematology(
- Contribution to journal › Letter
-
Mark
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants
(
- Contribution to journal › Letter
-
Mark
Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia
2021) In International Journal of Laboratory Hematology(
- Contribution to journal › Article